Header2

Renal Cell Carcinoma

ISBN: 978-1-60795-003-5

9781607950035

Price
$79.95

 


May 2009
313 Pages
ISBN 978-1-60795 003 5
US $99.95

Brian I. Rini, MD
Associate Professor
Department of Solid Tumor Oncology and Urology
Cleveland Clinic Taussig Cancer Center
Associate Professor of Medicine
Cleveland Clinic Foundation/ Case Western Reserve
 University Lerner College of Medicine
Cleveland, OH
 
Steven C. Campbell, MD, PhD
Professor of Surgery
Section of Urological Oncology
Glickman Urological Institute
Cleveland Clinic Foundation
Cleveland, OH
 

Description

The treatment of kidney cancer has been re-energized by the introduction of novel therapeutics and innovative surgical advances. Edited and written by medical oncologists and surgeons, this new reference covers the full spectrum of renal cell carcinoma from screening, epidemiology, and pathology to molecular genetics, surgical management, and therapy of metastatic disease.

Front and center is the biology of renal cell carcinoma, where researchers have made great progress in expanding our understanding of mechanisms and processes making therapeutic advances possible. This atlas includes the latest information on the immunobiology of kidney cancer as well as pathways involving vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR). The bulk of the chapters deal with the practical management of the continuum of kidney cancer ranging from the small renal mass, through locally advanced disease, to the metastatic patient. 

Different treatment approaches are discussed within the context of each of these clinical scenarios, and surgical and therapeutic advances are highlighted. In addition, special populations such as patients requiring palliative care, those with brain or bone metastasis, and those with inherited renal cell carcinoma are discussed.

Key Features

  • Up to date discussion of the newest data on targeted agents
  • Comprehensive analysis of all aspects of RCC management
  • Chapters of special clinical interests including Partial Nephrectomy,  Angiogenesis  Biology, and Rapamycin Inhibition
  • Extensive details on new research pathways in VEGF and mTOR
  • Extensive description of imaging techniques